Pulse radiation could supercharge immunotherapy against cancer
NCT ID NCT07381231
First seen Feb 02, 2026 · Last updated Jun 22, 2026 · Updated 24 times
Summary
This phase 2 trial tests whether adding a special type of radiation called adaptive pulse radiotherapy to standard immunotherapy can help treat advanced solid tumors. The study will enroll 35 people with various cancers who are already receiving or planning to receive immune checkpoint inhibitors. Participants will get 2-3 high-dose radiation sessions alongside their usual immunotherapy, with the radiation target adjusted based on tumor response. Researchers will track tumor shrinkage, survival, side effects, and quality of life.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for CANCER are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Samsung medical center
RECRUITINGSeoul, 06351, South Korea
Contact Phone: •••-•••-•••• Email: •••••@•••••
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
Adaptive Pulse Radiotherapy (Pulse RT) combined with immune checkpoint inhibitors (ICIs)
What this could lead to
If it works, this could point toward a more effective way to treat advanced solid tumors by boosting the immune system's ability to fight cancer.
What could go wrong
This is a small, early-phase study with only 35 participants, so results may not apply to everyone. The combination therapy could also cause unexpected side effects.
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.